| 2.48 0.06 (2.48%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.28  |
1-year : | 3.6 |
| Resists | First : | 2.81 |
Second : | 3.08 |
| Pivot price | 2.56 |
|||
| Supports | First : | 2.35 | Second : | 1.96 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 2.59 |
| MA(100) : | 3.39 |
MA(250) : | 2.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.6 |
D(3) : | 7.4 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 4.59 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELDN ] has closed above bottom band by 33.8%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.56 - 2.57 | 2.57 - 2.58 |
| Low: | 2.39 - 2.4 | 2.4 - 2.42 |
| Close: | 2.46 - 2.48 | 2.48 - 2.5 |
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Mon, 05 Oct 2026
Eledon Pharmaceuticals Announces Presentation at the - GlobeNewswire
Mon, 05 Oct 2026
A kidney transplant study will spotlight what patients report on Oct. 23 - Stock Titan
Wed, 23 Sep 2026
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Earnings & Company Profile - RTTNews
Tue, 22 Sep 2026
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
Tue, 22 Sep 2026
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha
Sat, 25 Jul 2026
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 81 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 58.6 (%) |
| Shares Short | 7,850 (K) |
| Shares Short P.Month | 7,750 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -110.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -2.76 |
| PEG Ratio | 0 |
| Price to Book value | 2.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|